 | Up a level |
Harrington, Kevin J. and Burtness, Barbara and Greil, Richard and Soulieres, Denis and Tahara, Makoto and de Castro Jr, Gilberto and Psyrri, Amanda and Brana, Irene and Baste, Neus and Neupane, Prakash and Bratland, Ase and Fuereder, Thorsten and Hughes, Brett G. M. and Mesia, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Wan Ishak, Wan Zamaniah and Lin, Jianxin and Gumuscu, Burak and Swaby, Ramona F. and Rischin, Danny (2023) Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Opdated results of the phase III keynote-048 study. Journal of Clinical Oncology, 41 (4). 790+. ISSN 0732183X, DOI https://doi.org/10.1200/JCO.21.02508.
Rischin, Danny and Harrington, Kevin J. and Greil, Richard and Soulieres, Denis and Tahara, Makoto and de Castro Jr, Gilberto and Psyrri, Amanda and Brana, Irene and Neupane, Prakash and Bratland, Ase and Fuereder, Thorsten and Hughes, Brett G. M. and Mesia, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Ishak, Wan Zamaniah Wan and Hong, Ruey-Long and Mendoza, Rene Gonzalez and Jia, Liyi and Chirovsky, Diana and Norquist, Josephine and Jin, Fan and Burtness, Barbara (2022) Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128. ISSN 1368-8375, DOI https://doi.org/10.1016/j.oraloncology.2022.105815.
